Forced vital capacity trajectories in patients with idiopathic pulmonary fibrosis: a secondary analysis of a multicentre, prospective, observational cohort

被引:17
作者
Fainberg, Hernan P. [1 ]
Oldham, Justin M. [2 ]
Molyneaux, Philip L. [1 ,3 ,4 ]
Allen, Richard J. [5 ]
Kraven, Luke M. [5 ]
Fahy, William A. [6 ]
Porte, Joanne [7 ]
Braybrooke, Rebecca [7 ]
Saini, Gauri [7 ]
Karsdal, Morten A. [9 ]
Leeming, Diane J. [9 ]
Sand, Jannie M. B. [9 ]
Triguero, Isaac [8 ,10 ]
Oballa, Eunice [3 ,4 ,6 ]
Wells, Athol U. [1 ]
Renzoni, Elisabetta [1 ,3 ,4 ]
Wain, Louise, V [5 ,11 ]
Noth, Imre [12 ]
Maher, Toby M. [1 ,3 ,4 ,13 ]
Stewart, Iain D. [1 ]
Jenkins, R. Gisli [1 ,3 ,4 ]
机构
[1] Imperial Coll London, Natl Heart & Lung Inst, London, England
[2] Univ Michigan, Div Pulm & Crit Care Med, Ann Arbor, MI USA
[3] Guys & St Thomas NHS Fdn Trust, Royal Brompton Hosp, London, England
[4] Guys & St Thomas NHS Fdn Trust, Harefield Hosp, London, England
[5] Univ Leicester, Dept Hlth Sci, Leicester, Leics, England
[6] GlaxoSmithKline Med Res Ctr, Discovery Med, Stevenage, Herts, England
[7] NIHR Biomed Res Ctr, Nottingham Resp Res Unit, Nottingham, England
[8] Univ Nottingham, Sch Comp Sci, Computat Optimisat & Learning Lab, Nottingham, England
[9] Nordic Biosci, Herlev, Denmark
[10] Univ Granada, Andalusian Inst Data Sci AndComputat Intelligence, Granada, Spain
[11] Glenfield Hosp, Leicester Resp Biomed Res Ctr, Natl Inst Hlth Res, Leicester, Leics, England
[12] Univ Virginia, Pulm & Crit Care Med, Charlottesville, VA USA
[13] Univ Southern Calif, Keck Sch Med, Los Angeles, CA USA
来源
LANCET DIGITAL HEALTH | 2022年 / 4卷 / 12期
基金
英国医学研究理事会;
关键词
PHASE-3; TRIAL; DOUBLE-BLIND; PIRFENIDONE; IPF; MORTALITY;
D O I
10.1016/S2589-7500(22)00173-X
中图分类号
R-058 [];
学科分类号
摘要
Background Idiopathic pulmonary fibrosis is a progressive fibrotic lung disease with a variable clinical trajectory. Decline in forced vital capacity (FVC) is the main indicator of progression; however, missingness prevents long-term analysis of patterns in lung function. We aimed to identify distinct clusters of lung function trajectory among patients with idiopathic pulmonary fibrosis using machine learning techniques. Methods We did a secondary analysis of longitudinal data on FVC collected from a cohort of patients with idiopathic pulmonary fibrosis from the PROFILE study; a multicentre, prospective, observational cohort study. We evaluated the imputation performance of conventional and machine learning techniques to impute missing data and then analysed the fully imputed dataset by unsupervised clustering using self-organising maps. We compared anthropometric features, genomic associations, serum biomarkers, and clinical outcomes between clusters. We also performed a replication of the analysis on data from a cohort of patients with idiopathic pulmonary fibrosis from an independent dataset, obtained from the Chicago Consortium. Findings 415 (71%) of 581 participants recruited into the PROFILE study were eligible for further analysis. An unsupervised machine learning algorithm had the lowest imputation error among tested methods, and self-organising maps identified four distinct clusters (1-4), which was confirmed by sensitivity analysis. Cluster 1 comprised 140 (34%) participants and was associated with a disease trajectory showing a linear decline in FVC over 3 years. Cluster 2 comprised 100 (24%) participants and was associated with a trajectory showing an initial improvement in FVC before subsequently decreasing. Cluster 3 comprised 113 (27%) participants and was associated with a trajectory showing an initial decline in FVC before subsequent stabilisation. Cluster 4 comprised 62 (15%) participants and was associated with a trajectory showing stable lung function. Median survival was shortest in cluster 1 (2 center dot 87 years [IQR 2 center dot 29-3 center dot 40]) and cluster 3 (2 center dot 23 years [1 center dot 75-3 center dot 84]), followed by cluster 2 (4 center dot 74 years [3 center dot 96-5 center dot 73]), and was longest in cluster 4 (5 center dot 56 years [5 center dot 18-6 center dot 62]). Baseline FEV1 to FVC ratio and concentrations of the biomarker SP-D were significantly higher in clusters 1 and 3. Similar lung function clusters with some shared anthropometric features were identified in the replication cohort. Interpretation Using a data-driven unsupervised approach, we identified four clusters of lung function trajectory with distinct clinical and biochemical features. Enriching or stratifying longitudinal spirometric data into clusters might optimise evaluation of intervention efficacy during clinical trials and patient management. Copyright (c) 2022 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
引用
收藏
页码:E862 / E872
页数:11
相关论文
共 30 条
  • [11] A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
    King, Talmadge E., Jr.
    Bradford, Williamson Z.
    Castro-Bernardini, Socorro
    Fagan, Elizabeth A.
    Glaspole, Ian
    Glassberg, Marilyn K.
    Gorina, Eduard
    Hopkins, Peter M.
    Kardatzke, David
    Lancaster, Lisa
    Lederer, David J.
    Nathan, Steven D.
    Pereira, Carlos A.
    Sahn, Steven A.
    Sussman, Robert
    Swigris, Jeffrey J.
    Noble, Paul W.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (22) : 2083 - 2092
  • [12] Random forest-based imputation outperforms other methods for imputing LC-MS metabolomics data: a comparative study
    Kokla, Marietta
    Virtanen, Jyrki
    Kolehmainen, Marjukka
    Paananen, Jussi
    Hanhineva, Kati
    [J]. BMC BIOINFORMATICS, 2019, 20 (01)
  • [13] IPF and CPFE - the two different entities or two different presentations of the same disease?
    Kwiatkowska, Sylwia
    [J]. ADVANCES IN RESPIRATORY MEDICINE, 2018, 86 (01) : 23 - 26
  • [14] Sensitivity Analyses of the Change in FVC in a Phase 3 Trial of Pirfenidone for Idiopathic Pulmonary Fibrosis
    Lederer, David J.
    Bradford, Williamson Z.
    Fagan, Elizabeth A.
    Glaspole, Ian
    Glassberg, Marilyn K.
    Glasscock, Kenneth F.
    Kardatzke, David
    King, Talmadge E., Jr.
    Lancaster, Lisa H.
    Nathan, Steven D.
    Pereira, Carlos A.
    Sahn, Steven A.
    Swigris, Jeffrey J.
    Noble, Paul W.
    [J]. CHEST, 2015, 148 (01) : 196 - 201
  • [15] Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial
    Maher, Toby M.
    Corte, Tamera J.
    Fischer, Aryeh
    Kreuter, Michael
    Lederer, David J.
    Molina-Molina, Maria
    Axmann, Judit
    Kirchgaessler, Klaus-Uwe
    Samara, Katerina
    Gilberg, Frank
    Cottin, Vincent
    [J]. LANCET RESPIRATORY MEDICINE, 2020, 8 (02) : 147 - 157
  • [16] Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis
    Nathan, Steven D.
    Albera, Carlo
    Bradford, Williamson Z.
    Costabel, Ulrich
    du Bois, Roland M.
    Fagan, Elizabeth A.
    Fishman, Robert S.
    Glaspole, Ian
    Glassberg, Marilyn K.
    Glasscock, Kenneth F.
    King, Talmadge E., Jr.
    Lancaster, Lisa
    Lederer, David J.
    Lin, Zhengning
    Pereira, Carlos A.
    Swigris, Jeffrey J.
    Valeyre, Dominique
    Noble, Paul W.
    Wells, Athol U.
    [J]. THORAX, 2016, 71 (05) : 429 - 435
  • [17] Long-term Course and Prognosis of Idiopathic Pulmonary Fibrosis in the New Millennium
    Nathan, Steven D.
    Shlobin, Oksana A.
    Weir, Nargues
    Ahmad, Shahzad
    Kaldjob, Julienne M.
    Battle, Edwinia
    Sheridan, Michael J.
    du Bois, Roland M.
    [J]. CHEST, 2011, 140 (01) : 221 - 229
  • [18] Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials
    Noble, Paul W.
    Albera, Carlo
    Bradford, Williamson Z.
    Costabel, Ulrich
    Glassberg, Marilyn K.
    Kardatzke, David
    King, Talmadge E., Jr.
    Lancaster, Lisa
    Sahn, Steven A.
    Szwarcberg, Javier
    Valeyre, Dominique
    du Bois, Roland M.
    [J]. LANCET, 2011, 377 (9779) : 1760 - 1769
  • [19] Genetic variants associated with idiopathic pulmonary fibrosis susceptibility and mortality: a genome-wide association study
    Noth, Imre
    Zhang, Yingze
    Ma, Shwu-Fan
    Flores, Carlos
    Barber, Mathew
    Huang, Yong
    Broderick, Steven M.
    Wade, Michael S.
    Hysi, Pirro
    Scuirba, Joseph
    Richards, Thomas J.
    Juan-Guardela, Brenda M.
    Vij, Rekha
    Han, MeiLan K.
    Martinez, Fernando J.
    Kossen, Karl
    Seiwert, Scott D.
    Christie, Jason D.
    Nicolae, Dan
    Kaminski, Naftali
    Garcia, Joe G. N.
    [J]. LANCET RESPIRATORY MEDICINE, 2013, 1 (04) : 309 - 317
  • [20] An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis An Update of the 2011 Clinical Practice Guideline
    Raghu, Ganesh
    Rochwerg, Bram
    Zhang, Yuan
    Garcia, Carlos A. Cuello
    Azuma, Arata
    Behr, Juergen
    Brozek, Jan L.
    Collard, Harold R.
    Cunningham, William
    Homma, Sakae
    Johkoh, Takeshi
    Martinez, Fernando J.
    Myers, Jeffrey
    Protzko, Shandra L.
    Richeldi, Luca
    Rind, David
    Selman, Moises
    Theodore, Arthur
    Wells, Athol U.
    Hoogsteden, Henk
    Schuenemann, Holger J.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2015, 192 (02) : E3 - E19